Hepamerz%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528l-Ornithine%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520l-Aspartate%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520-%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520lola%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

# Hepamerz (l-Ornithine l-Aspartate) ## Overview Hepamerz is a combination of l-ornithine and l-aspartate, amino acids involved in the urea cycle and protein synthesis. It is used to treat hyperammonemia associated with liver disease. ## Primary Indications Treatment of latent and overt hepatic encephalopathy (HE) in patients with cirrhosis. ## Adult Dosing * **Overt HE:** Typically initiated with 5g intravenously (IV) every 8 hours. Doses can be increased up to 10g IV every 8 hours if needed, based on clinical response and ammonia levels. * **Latent HE:** Typically 3g orally (PO) three times daily. * **Switch to PO:** After initial IV treatment for overt HE, patients may be transitioned to oral therapy, usually 3g PO three times daily, or higher doses as tolerated and indicated. ## Pediatric Dosing * There is **limited established pediatric dosing data** for Hepamerz. Use in pediatric populations should be guided by expert clinical judgment and careful monitoring. ## Dose Adjustments * No specific dose adjustments are routinely recommended for renal or hepatic impairment, but caution and close monitoring are advised in patients with severe liver dysfunction. ## Contraindications * Known hypersensitivity to l-ornithine or l-aspartate. * Severe impairment of kidney function (creatinine clearance < 25 mL/min) is a relative contraindication due to potential accumulation of amino acids. ## Adverse Effects * **Common:** Nausea, vomiting, abdominal pain, diarrhea, flatulence. * **Less Common:** Dizziness, headache, fatigue, skin rash. * **Rare:** Allergic reactions. ## Key Drug Interactions * No significant drug interactions have been well-documented. However, due to its metabolism and excretion, caution with other renally or hepatically cleared medications may be warranted. ## Monitoring * Serum ammonia levels. * Mental status and neurological function. * Renal function (especially in those with underlying kidney issues). * Electrolytes. ## Clinical Pearls * Hepamerz works by stimulating the urea cycle to detoxify ammonia in the liver and by promoting the synthesis of glutamine in the brain, which can also help reduce ammonia levels. * The oral formulation may be less effective than IV for acute management of overt HE. * Effectiveness is dependent on adequate liver function to utilize the amino acids. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the current prescribing information and relevant guidelines for definitive guidance. Local protocols may vary.